Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2021.11.003
Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira
Introduction
The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).
Material and methods
We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0 mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24 h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.
Results
The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.
Conclusions
Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.
{"title":"The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression","authors":"Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira","doi":"10.1016/j.rpsmen.2021.11.003","DOIUrl":"10.1016/j.rpsmen.2021.11.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 212-217"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S217350502100056X/pdfft?md5=bdbad88de76679369909ec10058b5c2d&pid=1-s2.0-S217350502100056X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2021.06.001
Alejandro de la Torre-Luque , Jose Luis Ayuso-Mateos
{"title":"Depression in late life: Linking the immunometabolic dysregulation with clinical features","authors":"Alejandro de la Torre-Luque , Jose Luis Ayuso-Mateos","doi":"10.1016/j.rpsmen.2021.06.001","DOIUrl":"10.1016/j.rpsmen.2021.06.001","url":null,"abstract":"","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 181-185"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000595/pdfft?md5=1c5a9e460ddcd7cefb4be42eed254307&pid=1-s2.0-S2173505021000595-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2021.11.004
Nora Olazabal , Sonia Bustamante , M. Aranzazu Madrazo , Luis Osa , Ana M. O’Neill of Tyrone , Ana Catalán , Miguel Angel González-Torres
{"title":"Real clinical setting intravenous ketamine use for treatment resistant depression: 12 month follow-up after initial response","authors":"Nora Olazabal , Sonia Bustamante , M. Aranzazu Madrazo , Luis Osa , Ana M. O’Neill of Tyrone , Ana Catalán , Miguel Angel González-Torres","doi":"10.1016/j.rpsmen.2021.11.004","DOIUrl":"10.1016/j.rpsmen.2021.11.004","url":null,"abstract":"","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 227-229"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000583/pdfft?md5=575cf7162d2f0fbd2d1dbb560c537ab9&pid=1-s2.0-S2173505021000583-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2021.01.001
Adrián Alacreu-Crespo , Lucas Giner , Philippe Courtet
{"title":"Psychiatric patients are more vulnerable to the Spanish euthanasia law?","authors":"Adrián Alacreu-Crespo , Lucas Giner , Philippe Courtet","doi":"10.1016/j.rpsmen.2021.01.001","DOIUrl":"10.1016/j.rpsmen.2021.01.001","url":null,"abstract":"","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 231-233"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000534/pdfft?md5=8c20b71f9ae05bb2fa5763bfe11f0177&pid=1-s2.0-S2173505021000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39902026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2019.12.004
Celso Iglesias García , Pilar López García , José Luis Ayuso Mateos , José Ángel García , Julio Bobes
Introduction
The World Health Organization has developed a new classification of mental disorders in Primary Health Care (PHC), the ICD-11-PHC, in which there are changes in the diagnostic criteria of anxiety and depression disorder. In addition, 2 screening instruments have been developed for the detection of anxious and depressive symptoms according to the criteria of the new classification.
Objectives
To evaluate the capacity of the Spanish version of the 2 brief scales Dep5 and Anx5 to identify cases of depression and anxiety in PHC in Spain.
Method
A cross-sectional study conducted by 37 PHC physicians who selected 284 patients with suspected emotional distress. This sample was administered the screening scales (Anx5 and Dep5) and a diagnostic instrument (Clinical Interview Schedule-Revised) contemplating the new ICD-11 criteria as used as gold standard.
Results
The Anx5, using a cut-off point of 3, showed a sensitivity of 0.75 and specificity of 0.53. Using a cut-off point of 4, the Dep5 showed a sensitivity of 0.48 and a specificity of 0.8. The 2 scales together, with a cut-off point of 3 for each, classified correctly 73,57% as cases or non-cases. The diagnosis most frequently observed was anxious depression.
Conclusions
The screening scales for anxious and depressive symptoms (Anx5 and Dep5) are simple and easy-to-use instruments for assessing anxious and depressive symptoms in PHC. The reliability and validity data of each of the scales separately are limited but the figures improve when they are used together.
{"title":"Screening for anxiety and depression in Primary Care: Utility of 2 brief scales adapted to the ICD-11-PC","authors":"Celso Iglesias García , Pilar López García , José Luis Ayuso Mateos , José Ángel García , Julio Bobes","doi":"10.1016/j.rpsmen.2019.12.004","DOIUrl":"10.1016/j.rpsmen.2019.12.004","url":null,"abstract":"<div><h3>Introduction</h3><p>The World Health Organization has developed a new classification of mental disorders in Primary Health Care (PHC), the ICD-11-PHC, in which there are changes in the diagnostic criteria of anxiety and depression disorder. In addition, 2 screening instruments have been developed for the detection of anxious and depressive symptoms according to the criteria of the new classification.</p></div><div><h3>Objectives</h3><p>To evaluate the capacity of the Spanish version of the 2 brief scales Dep5 and Anx5 to identify cases of depression and anxiety in PHC in Spain.</p></div><div><h3>Method</h3><p>A cross-sectional study conducted by 37 PHC physicians who selected 284 patients with suspected emotional distress. This sample was administered the screening scales (Anx5 and Dep5) and a diagnostic instrument (Clinical Interview Schedule-Revised) contemplating the new ICD-11 criteria as used as gold standard.</p></div><div><h3>Results</h3><p>The Anx5, using a cut-off point of 3, showed a sensitivity of 0.75 and specificity of 0.53. Using a cut-off point of 4, the Dep5 showed a sensitivity of 0.48 and a specificity of 0.8. The 2 scales together, with a cut-off point of 3 for each, classified correctly 73,57% as cases or non-cases. The diagnosis most frequently observed was anxious depression.</p></div><div><h3>Conclusions</h3><p>The screening scales for anxious and depressive symptoms (Anx5 and Dep5) are simple and easy-to-use instruments for assessing anxious and depressive symptoms in PHC. The reliability and validity data of each of the scales separately are limited but the figures improve when they are used together.</p></div>","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 196-201"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000510/pdfft?md5=29487cb1088db44c571db1a1fd5a9b29&pid=1-s2.0-S2173505021000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39902024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01DOI: 10.1016/j.rpsmen.2020.12.002
Arantxa Orozco , Narcís Cardoner , Cristina F. Aragón , Salvador Ruiz-Murugarren , María Vicens , Miguel Ángel Álvarez-Mon , Guillermo Lahera
Introduction
A high prevalence of obsessive–compulsive symptoms (OCSs) in anxiety-depressive disorders ranging from 30 to 67% has been described.
Objective
This study aims to assess the presence and persistence of OCSs in an outpatient sample of subjects with anxiety and depressive disorders, as well as its relationship with recent life events (RLEs) and/or traumatic experiences (TEs).
Method
We conducted a prospective, observational, analytical study of 200 subjects with DSM-5 diagnoses of anxiety and/or depression. Participants were included by consecutive sampling and were evaluated at baseline and after 6–12 months (mean 8.5 months) of follow-up. The severity of the symptoms was assessed through the Hamilton Anxiety Scale (HARS) and Hamilton Scale for the evaluation of depression (HRSD-17), and comorbidity was assessed through the International Neuropsychiatric Interview (MINI). The Revised Inventory of Obsessions and Compulsions (OCI-R), the Recent Vital Changes Questionnaire (CVSV), and the Diagnostic Scale for Post-Traumatic Stress (PDS) were also administered.
Results
54% of the sample presented OCSs, and 30.5% presented one or more TEs throughout life. At the baseline visit, the presence of OCSs was associated with the severity of depressive symptoms (p = 0.028), the presence of TEs (p < 0.01), symptoms of post-traumatic stress disorder (p < 0.01) and the number of RLEs (p < 0.01). Response rate at follow-up was 38%, and persistence of OCSs was found in 60.5% of patients, independent of depressive or anxious symptoms, but was associated with the number of RLEs (p < 0.01).
Conclusion
The presence of OCSs in patients with anxiety and depressive disorders is frequent and persistent. Anxious-depressive patients with a history of TEs and RLEs had higher OCS levels. These findings highlight the importance of early detection and the use of therapeutic strategies focused on resilience to stress and trauma.
{"title":"Obsessive–compulsive symptoms in anxiety and depressive disorders: Influence of recent and/or traumatic life events","authors":"Arantxa Orozco , Narcís Cardoner , Cristina F. Aragón , Salvador Ruiz-Murugarren , María Vicens , Miguel Ángel Álvarez-Mon , Guillermo Lahera","doi":"10.1016/j.rpsmen.2020.12.002","DOIUrl":"10.1016/j.rpsmen.2020.12.002","url":null,"abstract":"<div><h3>Introduction</h3><p>A high prevalence of obsessive–compulsive symptoms (OCSs) in anxiety-depressive disorders ranging from 30 to 67% has been described.</p></div><div><h3>Objective</h3><p>This study aims to assess the presence and persistence of OCSs in an outpatient sample of subjects with anxiety and depressive disorders, as well as its relationship with recent life events (RLEs) and/or traumatic experiences (TEs).</p></div><div><h3>Method</h3><p>We conducted a prospective, observational, analytical study of 200 subjects with DSM-5 diagnoses of anxiety and/or depression. Participants were included by consecutive sampling and were evaluated at baseline and after 6–12 months (mean 8.5 months) of follow-up. The severity of the symptoms was assessed through the Hamilton Anxiety Scale (HARS) and Hamilton Scale for the evaluation of depression (HRSD-17), and comorbidity was assessed through the International Neuropsychiatric Interview (MINI). The Revised Inventory of Obsessions and Compulsions (OCI-R), the Recent Vital Changes Questionnaire (CVSV), and the Diagnostic Scale for Post-Traumatic Stress (PDS) were also administered.</p></div><div><h3>Results</h3><p>54% of the sample presented OCSs, and 30.5% presented one or more TEs throughout life. At the baseline visit, the presence of OCSs was associated with the severity of depressive symptoms (<em>p</em> <!-->=<!--> <!-->0.028), the presence of TEs (<em>p</em> <!--><<!--> <!-->0.01), symptoms of post-traumatic stress disorder (<em>p</em> <!--><<!--> <!-->0.01) and the number of RLEs (<em>p</em> <!--><<!--> <!-->0.01). Response rate at follow-up was 38%, and persistence of OCSs was found in 60.5% of patients, independent of depressive or anxious symptoms, but was associated with the number of RLEs (<em>p</em> <!--><<!--> <!-->0.01).</p></div><div><h3>Conclusion</h3><p>The presence of OCSs in patients with anxiety and depressive disorders is frequent and persistent. Anxious-depressive patients with a history of TEs and RLEs had higher OCS levels. These findings highlight the importance of early detection and the use of therapeutic strategies focused on resilience to stress and trauma.</p></div>","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 4","pages":"Pages 218-226"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000571/pdfft?md5=3ccac90467908b492f20e208b671a3c0&pid=1-s2.0-S2173505021000571-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1016/j.rpsmen.2021.07.003
Emilio Fernández-Egea
{"title":"Waiting for Godot or the use of biomarkers in clinical practice","authors":"Emilio Fernández-Egea","doi":"10.1016/j.rpsmen.2021.07.003","DOIUrl":"10.1016/j.rpsmen.2021.07.003","url":null,"abstract":"","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 3","pages":"Pages 123-124"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000431/pdfft?md5=3aaa0cd43ff96870d423fb3ff3210ef5&pid=1-s2.0-S2173505021000431-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39364130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1016/j.rpsmen.2020.10.002
Manuel Delgado-Alvarado , Javier Vázquez-Bourgon , Rosa Ayesa-Arriola , Victor Ortiz-García de la Foz , Jacqueline Mayoral-van Son , Javier Labad , Benedicto Crespo-Facorro
{"title":"Predictive value of prolactin in first episode psychosis at ten years follow-up","authors":"Manuel Delgado-Alvarado , Javier Vázquez-Bourgon , Rosa Ayesa-Arriola , Victor Ortiz-García de la Foz , Jacqueline Mayoral-van Son , Javier Labad , Benedicto Crespo-Facorro","doi":"10.1016/j.rpsmen.2020.10.002","DOIUrl":"10.1016/j.rpsmen.2020.10.002","url":null,"abstract":"","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 3","pages":"Pages 179-180"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000406/pdfft?md5=53488fc24aa775e94b82af343701cbc0&pid=1-s2.0-S2173505021000406-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39364136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1016/j.rpsmen.2019.12.003
Carmen Dasí , Inmaculada Fuentes-Durá , Juan C. Ruiz , Marisa Navarro
Introduction
The present study aimed to obtain a short form of the Spanish version of the WAIS-IV for patients diagnosed with schizophrenia that requires about half an hour to be administered. The reduced test can be very useful in clinical and research settings when an estimation of the intelligence quotient (IQ) is required to decide about intervention programs or to describe the sample.
Materials and methods
A sample of 143 patients participated in the study, 91 out of them were the test group, and the other 52 were used for a cross-validation analysis. To increase the content validity, the decision was made to create a short form composed of a subtest of each of the four cognitive domains that the scale measures.
Results
Several analyses showed that the best combination was composed of the Information, Block Design, Arithmetic, and Symbol Search subtests. Nine different criteria were calculated to evaluate the quality of the short form.
Conclusions
The data showed very good results for the criteria: correlations, difference of means, and cross-validation. The results were satisfactory for: category agreement, band of error, clinical accuracy, and reliability.
{"title":"Four-subtest short-form of the WAIS-IV for assessment of patients diagnosed with schizophrenia","authors":"Carmen Dasí , Inmaculada Fuentes-Durá , Juan C. Ruiz , Marisa Navarro","doi":"10.1016/j.rpsmen.2019.12.003","DOIUrl":"10.1016/j.rpsmen.2019.12.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The present study aimed to obtain a short form of the Spanish version of the WAIS-IV for patients diagnosed with schizophrenia that requires about half an hour to be administered. The reduced test can be very useful in clinical and research settings when an estimation of the intelligence quotient (IQ) is required to decide about intervention programs or to describe the sample.</p></div><div><h3>Materials and methods</h3><p>A sample of 143 patients participated in the study, 91 out of them were the test group, and the other 52 were used for a cross-validation analysis. To increase the content validity, the decision was made to create a short form composed of a subtest of each of the four cognitive domains that the scale measures.</p></div><div><h3>Results</h3><p>Several analyses showed that the best combination was composed of the Information, Block Design, Arithmetic, and Symbol Search subtests. Nine different criteria were calculated to evaluate the quality of the short form.</p></div><div><h3>Conclusions</h3><p>The data showed very good results for the criteria: correlations, difference of means, and cross-validation. The results were satisfactory for: category agreement, band of error, clinical accuracy, and reliability.</p></div>","PeriodicalId":101104,"journal":{"name":"Revista de Psiquiatría y Salud Mental (English Edition)","volume":"14 3","pages":"Pages 139-147"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173505021000364/pdfft?md5=b5cf5d7161cb0f6d8a98f9793a9a67b5&pid=1-s2.0-S2173505021000364-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39287247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号